Clinical predictors of response to cetuximabchemotherapy in metastatic colorectal cancer
Publication in refereed journal

Full Text

Times Cited

Other information
AbstractObjective To identify clinical markers to predict which patients with advanced colorectal cancers are likely to benefit from cetuximabchemotherapy. Design Retrospective review. Setting Oncology unit in a university teaching hospital in Hong Kong. Patients A total of 102 patients with metastatic colorectal cancer treated with cetuximab-chemotherapy. Main outcome measures Correlation of multiple potential clinical predictive factors with tumour response to cetuximab-chemotherapy. Results The objective response rates to cetuximab plus chemotherapy were 53% in patients receiving first-line treatment and 17% in previously treated patients. The univariate analysis indicated that fewer prior lines of chemotherapy (odds ratio=0.36; 95% confidence interval, 0.21-0.63; P<0.01) and development of cetuximab-related grade 3 rash (5.52; 1.62-18.76; P<0.01) were associated with significantly higher response rates. Multivariate analysis confirmed the independent predictive value of the number of prior chemotherapy regimens (odds ratio=0.37; 95% confidence interval, 0.20-0.69; P<0.01) and grade 3 rash (4.65; 1.21-19.29; P=0.03). Conclusions In this cohort of Chinese patients with advanced colorectal cancer, the presence of grade 3 rash and the number of prior chemotherapy regimens were independent predictors of response to cetuximab-chemotherapy. The utility of these clinical markers in clinical practice should be further evaluated together with established biomarkers.
All Author(s) ListMa A.T.W., Ma B.B.Y., Lei K.I.K., Mo F.K.F., Chan A.T.C.
Journal nameHong Kong Medical Journal
Volume Number16
Issue Number3
PublisherHong Kong Academy of Medicine Press
Place of PublicationHong Kong
Pages207 - 212
LanguagesEnglish-United Kingdom
KeywordsAntibodies, Colorectal neoplasms, Epidermal growth factor, Exanthema, Monoclonal, Neoplasm metastasis, Receptor

Last updated on 2021-22-09 at 23:40